B2M and neoplasm: Wang B et al. developed a hypoimmunogenic iPSC-derived T cell that lacks B2M, MHC-II, NK cell-ligand receptor CD155, and expresses single-chain MHC class I antigen E, while maintaining anti-tumor potency [87].